用3D打印技术生产药品，全国首张生产许可证落地南京；英伟达下一代Rubin芯片已流片丨智能制造日报

Group 1 - Nvidia's next-generation Rubin chips have been taped out, with plans for mass production next year, and data center capital expenditures expected to exceed $3 trillion over the next five years [2] - Nvidia's CFO announced that the Rubin architecture will include six chips, all of which have been taped out, and that data center revenue for Q2 FY2026 will include various components [2] - The GB200 and GB300 chips from the Blackwell architecture are still being shipped in Q3 [2] Group 2 - Hangzhou's Economic and Information Bureau is soliciting opinions on a three-year action plan to accelerate the development of the AI terminal industry, focusing on products like edge computing servers and AI servers equipped with domestic AI chips [2] - The plan includes developing high-performance integrated machines based on open-source models and creating secure and efficient desktop and laptop computers [2] Group 3 - Jiangsu Province has issued the first national production license for pharmaceuticals using 3D printing technology, marking a significant step in the R&D and industrialization of 3D printed drugs [3] - The licensed entity, Nanjing San Die Ji Pharmaceutical Technology Co., has a production capacity of 300 million 3D printed drug units annually, making it the largest commercial production base for 3D printed drugs globally [3] Group 4 - Yushu Technology has received authorization for a servo motor patent, which can be used for robotic joint drives or as a power device for toys [4]